Metys Pharmaceuticals
Metys Pharmaceuticals's email is info@metys-pharma.ch
and
Metys Pharmaceuticals's phone number is 41794087972
.
Metys Pharmaceuticals is developing MP-101 to prevent and treat chemotherapy-induced peripheral neuropathy, an uncomfortable and troubling side effect of several important cancer treatments. MP-101 is an orally-active modulator of glutamate signalling in spine and brain. Glutamate signalling has long been a sought-after target for the development of new central nervous system drug candidates. MP-101 is a particularly well-suited candidate, with outstanding pharmaceutic properties; it is a small molecule, obtained by a straight-forward chemical manufacturing process. It ...
read more
Metys Pharmaceuticals is developing MP-101 to prevent and treat chemotherapy-induced peripheral neuropathy, an uncomfortable and troubling side effect of several important cancer treatments. MP-101 is an orally-active modulator of glutamate signalling in spine and brain. Glutamate signalling has long been a sought-after target for the development of new central nervous system drug candidates. MP-101 is a particularly well-suited candidate, with outstanding pharmaceutic properties; it is a small molecule, obtained by a straight-forward chemical manufacturing process. It is also orally active in a wide range of rodent models of central nervous system disorders, such as depression, cognition, or neuropathic pain. MP-101 is a patent-pending non-racemic mixture of the left-handed and right-handed versions (the ''enantiomers'') of dimiracetam. It is not a one-to-one mixture (a ''racemate''), but a ratio that has been chosen because it is - unexpectedly - considerably more potent pharmacologically than the racemate. While the one-to-one mixture has long been known to be superior to either of the two single-handed enantiomers alone, Metys Pharmaceuticals has discovered that certain mixtures of dimiracetam enantiomers are far more potent still. Metys Pharmaceuticals has licensed the world-wide exclusive rights to racemic dimiracetam from Neurotune AG, including the entire dossier of regulatory studies supporting clinical trials of racemic dimiracetam. Metys Pharmaceuticals now aims to use these pharmacological, toxicological and clinical data obtained with racemic dimiracetam to support the future clinical trials of MP-101.
show less
Industry | Pharmaceuticals | |
Location | Switzerland | |
Employees | 3 | |
Founded | 2013 |
HQ | Leimenstrasse 57 | |
Phone | 4179-408-7972 | |
info@metys-pharma.ch | ||
Funding | 1,507,724 USD | |
Competitors | Walgreens Boots Allia..., Pfizer, Cvs Health, Novartis, Gsk, Bayer, |
Industry | Pharmaceuticals | |
Location | Switzerland | |
Employees | 3 | |
Founded | 2013 | |
linkedin.com/company/metys-pharmaceuticals | ||
HQ | Leimenstrasse 57 | |
Phone | 4179-408-7972 | |
info@metys-pharma.ch | ||
Funding | 1,507,724 USD |
Top Competitors for Metys Pharmaceuticals
Metys Pharmaceuticals Questions
Where are Metys Pharmaceuticals's headquarters?
Metys Pharmaceuticals's headquarters are in Leimenstrasse 57
What is Metys Pharmaceuticals's phone number?
Metys Pharmaceuticals's phone number is 41794087972
How many employees are working in Metys Pharmaceuticals right now?
Metys Pharmaceuticals has
3 employees.
View the Email and Phone Numbers for all 3 working at Metys Pharmaceuticals.
What is Metys Pharmaceuticals's industry?
Metys Pharmaceuticals's industry is
Pharmaceuticals
Who are Metys Pharmaceuticals's top competitors?
Metys Pharmaceuticals's top competitors are
Walgreens Boots Alliance
,
Pfizer
,
Cvs Health
,
Novartis
,
Gsk
,
Bayer
What is Metys Pharmaceuticals's email address?
Metys Pharmaceuticals's email address is info@metys-pharma.ch
What are Metys Pharmaceuticals's categories?
Metys Pharmaceuticals's categories are Medical, Medical Device, Pharmaceutical
What is Metys Pharmaceuticals's location?
Metys Pharmaceuticals's location is
Switzerland
When was Metys Pharmaceuticals's founded?
Metys Pharmaceuticals's founding year is 2013
What is Metys Pharmaceuticals's funding?
Metys Pharmaceuticals's funding is 1,507,724 USD
What is Metys Pharmaceuticals's current status?
Metys Pharmaceuticals's current status is acquired